Dare Bioscience (NASDAQ:DARE) has been given a $3.00 target price by analysts at Maxim Group in a research note issued to investors on Thursday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price objective would suggest a potential upside of 248.84% from the company’s current price.
Separately, ValuEngine upgraded Dare Bioscience from a “hold” rating to a “buy” rating in a research report on Tuesday, October 2nd.
Shares of NASDAQ:DARE opened at $0.86 on Thursday. The firm has a market cap of $11.19 million, a PE ratio of -0.69 and a beta of 2.37. Dare Bioscience has a 1 year low of $0.74 and a 1 year high of $3.59.
A hedge fund recently raised its stake in Dare Bioscience stock. Citadel Advisors LLC boosted its position in shares of Dare Bioscience Inc (NASDAQ:DARE) by 205.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 106,338 shares of the biotechnology company’s stock after acquiring an additional 71,470 shares during the quarter. Citadel Advisors LLC owned 0.93% of Dare Bioscience worth $104,000 at the end of the most recent reporting period. 7.56% of the stock is owned by institutional investors and hedge funds.
About Dare Bioscience
Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.
See Also: Asset Allocation
Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.